Literature DB >> 12506168

High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer.

N Hoogerbrugge1, P Bult, L M de Widt-Levert, L V Beex, L A Kiemeney, M J L Ligtenberg, L F Massuger, C Boetes, P Manders, H G Brunner.   

Abstract

PURPOSE: Women with a hereditary predisposition for breast cancer have an extremely high risk of developing invasive breast carcinoma, and many women consider prophylactic mastectomy to avoid this risk. The use of prophylactic mastectomy is still debated. Identification of frequent premalignant lesions in mastectomy specimens would support the preventive concept of prophylactic mastectomy. PATIENTS AND METHODS: We performed a prospective study of breast specimens from 67 women at extremely high genetic risk of breast cancer, with or without previous breast cancer, who were undergoing prophylactic mastectomy (66% were carriers of a BRCA1 or BRCA2 mutation). Breast specimens were studied by radiographic and macroscopic examination of 5-mm tissue slices, with subsequent histology of suspicious lesions and random samples from each quadrant of the breast and the nipple area.
RESULTS: In 57% of the women, one or more different types of high-risk histopathologic lesions were present: 37% atypical lobular hyperplasia, 39% atypical ductal hyperplasia, 25% lobular carcinoma-in-situ, and 15% ductal carcinoma-in-situ. A 4-mm invasive ductal carcinoma was found in one woman with ductal carcinoma-in-situ. None of these lesions was detected at palpation or mammography, which were performed before the mastectomy. The presence of high-risk lesions was independently related to age older than 40 years (odds ratio, 6.6; P =.01) and to bilateral oophorectomy before prophylactic mastectomy (odds ratio, 0.2; P = 0.02).
CONCLUSION: Many women at high risk of hereditary breast cancer develop high-risk histopathologic lesions, especially after the age of 40 years. Surveillance does not detect such high-risk histopathologic lesions.

Entities:  

Mesh:

Year:  2003        PMID: 12506168     DOI: 10.1200/JCO.2003.02.137

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  27 in total

1.  Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ.

Authors:  Soley Bayraktar; Nisreen Elsayegh; Angelica M Gutierrez Barrera; Heather Lin; Henry Kuerer; Tunc Tasbas; Kimberly I Muse; Kaylene Ready; Jennifer Litton; Funda Meric-Bernstam; Gabriel N Hortobagyi; Constance T Albarracin; Banu Arun
Journal:  Cancer       Date:  2011-08-25       Impact factor: 6.860

2.  p16(INK4a) expression and breast cancer risk in women with atypical hyperplasia.

Authors:  Derek C Radisky; Marta Santisteban; Hal K Berman; Mona L Gauthier; Marlene H Frost; Carol A Reynolds; Robert A Vierkant; V Shane Pankratz; Daniel W Visscher; Thea D Tlsty; Lynn C Hartmann
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-15

3.  The pathology of hereditary breast cancer.

Authors:  Emiliano Honrado; Javier Benítez; José Palacios
Journal:  Hered Cancer Clin Pract       Date:  2004-07-15       Impact factor: 2.857

4.  A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease.

Authors:  Mary L Disis; Ekram Gad; Daniel R Herendeen; Vy Phan- Lai; Kyong Hwa Park; Denise L Cecil; Megan M O'Meara; Piper M Treuting; Ronald A Lubet
Journal:  Cancer Prev Res (Phila)       Date:  2013-10-23

5.  Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer.

Authors:  Judy C Boughey; Tanya L Hoskin; Amy C Degnim; Thomas A Sellers; Joanne L Johnson; Melanie J Kasner; Lynn C Hartmann; Marlene H Frost
Journal:  Ann Surg Oncol       Date:  2010-09-19       Impact factor: 5.344

6.  Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing.

Authors:  Michael J Hall; Julia E Reid; Richard J Wenstrup
Journal:  Cancer Prev Res (Phila)       Date:  2010-12

7.  High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers.

Authors:  Banu Arun; Kristen J Vogel; Adriana Lopez; Mike Hernandez; Deann Atchley; Kristine R Broglio; Christopher I Amos; Funda Meric-Bernstam; Henry Kuerer; Gabriel N Hortobagyi; Constance T Albarracin
Journal:  Cancer Prev Res (Phila)       Date:  2009-01-27

Review 8.  Management updates for women with a BRCA1 or BRCA2 mutation.

Authors:  Rachel Nusbaum; Claudine Isaacs
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

9.  Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance.

Authors:  Robert M W Hofstra; Amanda B Spurdle; Diana Eccles; William D Foulkes; Niels de Wind; Nicoline Hoogerbrugge; Frans B L Hogervorst
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

10.  Short-term prophylactic tamoxifen reduces the incidence of antiestrogen-resistant/estrogen receptor-positive/progesterone receptor-negative mammary tumors.

Authors:  Teresa A Rose-Hellekant; Andrew J Skildum; Olga Zhdankin; Amy L Greene; Ronald R Regal; Katherine D Kundel; Donald W Kundel
Journal:  Cancer Prev Res (Phila)       Date:  2009-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.